CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Calendar Export
Debating optimal neoadjuvant therapy
(ID 336)
Lecture Time
19:30 - 19:40
Speakers
S. Tolaney
(Boston, MA, United States of America)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00